One Percent Tenofovir Applied Topically to Humanized BLT Mice and Used According to the CAPRISA 004 Experimental Design Demonstrates Partial Protection from Vaginal HIV Infection, Validating the BLT Model for Evaluation of New Microbicide Candidates

Recent iPrEx clinical trial results provided evidence that systemic preexposure prophylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) can partially prevent rectal HIV transmission in humans. Similarly, we have previously demonstrated that systemic administration of the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Denton, Paul W., Othieno, Florence, Martinez-Torres, Francisco, Zou, Wei, Krisko, John F., Fleming, Elisa, Zein, Sima, Powell, Daniel A., Wahl, Angela, Kwak, Youn Tae, Welch, Brett D., Kay, Michael S., Payne, Deborah A., Gallay, Philippe, Appella, Ettore, Estes, Jacob D., Lu, Min, Garcia, J. Victor
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2011
Aiheet:
Vaccines and Antiviral Agents
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147928/
https://ncbi.nlm.nih.gov/pubmed/21593172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00537-11
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia